Kiromic Biopharma, Inc.: directors' dealings · United States · SEC (Form 4)

About Kiromic Biopharma, Inc.

Kiromic Biopharma, Inc. (ticker: KRBP) is a U.S.-listed clinical-stage biopharmaceutical company traded on the NASDAQ (United States), focused on precision oncology and cell therapy. Founded in 2016 and headquartered in Houston, Texas, the company built its strategy around combining artificial intelligence, data mining, and biopharma development to identify therapeutic targets and advance immuno-oncology programs. Kiromic originally operated with a discovery-led model and later evolved into a more integrated organization spanning target identification, product development, and manufacturing preparation. Its Houston base gives it proximity to a major medical and research ecosystem, which is important for clinical collaboration and operational execution. The company’s core platform is DIAMOND®, its proprietary AI-driven target discovery engine. Using that platform, Kiromic has been developing cell and gene therapies with a strong emphasis on solid-tumor immunotherapy. Its lead program is Deltacel™, an allogeneic gamma delta T-cell therapy derived from donors and designed for solid cancers, with an initial clinical focus on metastatic non-small cell lung cancer (NSCLC). The company has also referenced other oncology programs, but Deltacel and the gamma delta T-cell platform are the main assets shaping its public investment profile today. From a competitive standpoint, Kiromic occupies a niche position relative to better-capitalized biotech peers. Its differentiation lies in two elements: an AI-based discovery workflow intended to accelerate target selection, and an allogeneic approach that could offer better scalability than some autologous cell therapies. That said, KRBP remains a highly speculative small-cap development company with substantial risks tied to clinical execution, regulatory approvals, capital access, and manufacturing scale-up. Investors should also note the company’s regulatory history: in 2024, the SEC announced settled charges related to undisclosed FDA review status issues, which is relevant when assessing governance quality and disclosure risk. Recent milestones include FDA Fast Track designation for Deltacel in 2024 and continued progress in the Deltacel-01 Phase 1 trial, including additional clinical site activation and early signs of tumor reduction reported in an initial patient. In 2025, the company also raised capital through a senior secured convertible note, reinforcing that liquidity and financing remain important themes. For French-speaking investors, KRBP should be viewed as a high-risk, event-driven biotechnology name listed on NASDAQ in the United States, where future value creation depends primarily on clinical validation of Deltacel, continued funding of trials, and disciplined regulatory execution.